Table 2.
Antitumour activity of PEP06 on postsurgical residual tumour xenografts of human LOVO colon cancer in nude mice
| Drug administration | Toxicity | Anticancer activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Group | Dose (mg·kg−1) | Schedule | Route | Average body weight (g, x ± s) | Death | Tumour weight (g) | IR (%) | Tumour volume (mm3) | IR (%) | |
| Start | Stop | |||||||||
| Control | – | QD × 17 | i.v. | 19.66 ± 0.67 | 21.26 ± 1.33 | 0/8 | 0.97 ± 0.43 | – | 1197.81 ± 726.72 | – |
| PEP06 | 20 | QD × 17 | i.v. | 19.65 ± 1.29 | 21.61 ± 1.31 | 0/8 | 0.31 ± 0.22 * | 68.2 | 319.36 ± 200.97 * | 73.3 |
| PEP06 | 10 | QD × 17 | i.v. | 20.25 ± 0.96 | 21.28 ± 1.28 | 0/8 | 0.54 ± 0.36 * | 44.7 | 430.30 ± 390.66 * | 64.1 |
The significance of differences (vs. control) was determined by one‐way ANOVA with t‐test. QD, every day.
*
P < 0.05 (n = 8, x ± s)